大B细胞淋巴瘤患者在CD19靶向嵌合抗原受体T细胞治疗后发生腺病毒引起的出血性膀胱炎。
Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
发表日期：2023 Sep 18
作者：
Irene Medina, Cecilia Carpio, Isabel Ruiz-Camps, Adaia Albasanz-Puig, Oriana Lopez-Godino, Juliana Esperalba, Francisco Beas, Mario Sanchez-Salinas, Gloria Iacoboni, Pere Barba
来源：
Experimental Hematology & Oncology
摘要：
靶向CD19的嵌合抗原受体（CAR）T细胞改变了难治性/复发性弥漫性大B细胞淋巴瘤患者的治疗现状。感染是CAR T细胞疗法后最常见的并发症之一。其中大多数感染是细菌性的，尽管病毒感染也可能在这种情况下发生。腺病毒引起的出血性膀胱炎是一种罕见的感染并发症，通常在骨髓或实体器官移植后才会观察到。在此，我们报告了一例在CAR T细胞输注后第一个月出现尿路症状的腺病毒引起的出血性膀胱炎病例。基于我们的经验和文献综述，我们讨论了CAR T细胞疗法后这种罕见感染的诊断方法和潜在治疗选择。
Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most frequent complications after CAR T-cell therapy. Most of these infections are bacterial, although viral infections can also occur in this setting. Adenovirus-induced hemorrhagic cystitis is a rare infectious complication and is usually observed after bone marrow or solid organ transplantation. Herein we report a case of adenovirus-induced hemorrhagic cystitis in a patient experiencing urinary symptoms within the first month after CAR T-cell infusion. Based on our experience and a literature review, we discuss the diagnostic approach and potential treatment options for this infrequent infection after CAR T-cell therapy.